Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Novartis' Sales Up 8.2% in 2009 Driven by Diovan, Glivec
February 22, 2010
- Cost Necessary to Revitalize Healthcare Estimated by a Team: Dr Adachi
February 22, 2010
- GSK's Sales Up 22% in Japan
February 22, 2010
- 9 New Drugs to Be Reviewed on February 26
February 22, 2010
- JMHA to Offer DB to Its Members to Compare Purchase Prices
February 22, 2010
- 4 Therapies Approved as Advanced Therapies
February 22, 2010
- METI to Foster Pharma Industry as Driver of Economic Growth
February 22, 2010
- Mergers May Take Place between Generic Companies: Mr Sawai
February 22, 2010
- Ethical Drugs Sales Up 4.2% in December: Crecon
February 22, 2010
- Daiichi Sankyo Applies for SUN Y7017 in Japan
February 22, 2010
- Prospects of Incretin-Related Drugs in Japan: 1
February 22, 2010
- Gemzar Approved for Breast Cancer in Japan: Ely Lilly
February 22, 2010
- Ranbaxy to Market Prasugrel in Mexico
February 22, 2010
- CDFS to Review Vectibix from Takeda
February 22, 2010
- Kyowa Kirin to Introduce Research Fellow System
February 22, 2010
- Taiyo to Increase Sales to Univ. Hospitals to Achieve ¥75 Bil. Sales by FY2013
February 22, 2010
- SRL to Acquire JCL
February 22, 2010
- Taiyo Yakuhin Recalls Tetipline Due to Adverse Reactions
February 22, 2010
- Toho to Enhance Pharmacy Business by Acquiring Medical Brain
February 22, 2010
- BI to Make SSP Wholly-Owned Subsidiary
February 22, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…